A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy
- 1 November 2015
- journal article
- Published by Elsevier in European Urology
- Vol. 68 (5) , 750-753
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical ProstatectomyJournal of Urology, 2015
- Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy miceMolecular Immunology, 2013
- Sildenafil citrate decreased natural killer cell activity and enhanced chance of successful pregnancy in women with a history of recurrent miscarriageFertility and Sterility, 2008
- The X-files in immunity: sex-based differences predispose immune responsesNature Reviews Immunology, 2008
- Exisulind in Combination with Celecoxib Modulates Epidermal Growth Factor Receptor, Cyclooxygenase-2, and Cyclin D1 against Prostate Carcinogenesis:In vivoEvidenceClinical Cancer Research, 2007
- Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cellsJournal of Cellular Biochemistry, 2004
- Management of prostate-specific antigen relapse in prostate cancer: A European consensusInternational Journal Of Clinical Practice, 2004
- Effect of Sildenafil Citrate on an Orthotopic Prostate Cancer Growth and Metastasis ModelJournal of Urology, 2003
- SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosisUrology, 1999